| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/22/2006 | EP1636186A1 2-hydroxymethyl-3,4,5-trihydroxy-1benzylpiperidine derivatives as inhibitors of glucosylceramide synthase (gcs) |
| 03/22/2006 | EP1636184A2 Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them |
| 03/22/2006 | EP1636181A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| 03/22/2006 | EP1635799A2 Pharmaceutical formulations of amyloid inhibiting compounds |
| 03/22/2006 | EP1635791A1 Pharmaceutical compositions comprising atorvastatin manufactured without granulation |
| 03/22/2006 | EP1497296B1 [1,4]DIAZOCINO[7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS |
| 03/22/2006 | EP1480951A4 Synthesis of indole thiazole compounds as ligands for the ah receptor |
| 03/22/2006 | EP1412357B1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 03/22/2006 | EP1406891B1 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 03/22/2006 | EP1404301A4 Stable controlled release pharmaceutical compositions containing pravastatin |
| 03/22/2006 | EP1366052B1 Novel multi-ring organic compounds for regulating gut motility and food intake |
| 03/22/2006 | EP1311522B1 New immunoeffector compounds |
| 03/22/2006 | EP1309324B1 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
| 03/22/2006 | EP1301516B1 Modulators of protein tyrosine phosphatases (ptpases) |
| 03/22/2006 | EP1272488B1 Tri-aryl-substituted-ethane pde4 inhibitors |
| 03/22/2006 | EP1220862B1 Purine derivatives |
| 03/22/2006 | EP1140924B1 Piperazine derivatives |
| 03/22/2006 | EP1139743B1 Exo-s-mecamylamine formulation and use in treatment |
| 03/22/2006 | EP1051161B1 Method for treating alzheimer's disease |
| 03/22/2006 | EP0915700B1 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| 03/22/2006 | CN1751046A Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments |
| 03/22/2006 | CN1751044A Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors |
| 03/22/2006 | CN1751038A Substituted aryl and heteroaryl derivatives as modulators of glucose metabolism and the prophylaxis and treatment of disorders thereof |
| 03/22/2006 | CN1751036A Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof |
| 03/22/2006 | CN1751019A Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
| 03/22/2006 | CN1750838A Medical drug containing fine particle of noble metal |
| 03/22/2006 | CN1750837A Superoxide anion decomposing agent |
| 03/22/2006 | CN1750758A Compounds for the treatment of metabolic disorders |
| 03/22/2006 | CN1749263A Several mark compounds of poacynum hendersonii woodson leaf |
| 03/22/2006 | CN1748794A Use of aza decyl meta pentalkenylone compounds |
| 03/22/2006 | CN1748793A Method for preparing cow foremilk immune globulin microcapsulation |
| 03/22/2006 | CN1748789A Medicine for reducing blood fat and its preparing method |
| 03/22/2006 | CN1748787A Pharmaceutical preparation containing p40 molecule or its gene |
| 03/22/2006 | CN1748771A Chinese medicine composition for treating diabetes and its preparing method and use |
| 03/22/2006 | CN1748765A Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
| 03/22/2006 | CN1748723A Poacynum hendersonii woodson leaf extract and blood fat reducing nfunction of two chemical component in it |
| 03/22/2006 | CN1748717A Method for prparing bee glue-ethyl cellulose microcapsule |
| 03/22/2006 | CN1748714A Method for preparing biological active substance of siphon-worm and its products |
| 03/22/2006 | CN1748675A Composition of rheinic acid compounds and preparing method and use for treating diabetes |
| 03/22/2006 | CN1748672A Aseptic medicine composition |
| 03/22/2006 | CN1246335C Recombinant IL-18 antagonist useful in treatment of IL-18 mediated disorders |
| 03/22/2006 | CN1246326C Pineapple flavonoid glycoside compound and its use |
| 03/22/2006 | CN1246311C Pyrrolidines which inhibit CAMP-specific PDE |
| 03/22/2006 | CN1246025C Medicine for treating diabetes and eye disease |
| 03/22/2006 | CN1246014C Blood fat lowering capsule or tablet and its preparation |
| 03/22/2006 | CN1246011C Use of lotus root joint extract in preparing medicine for improving human insulin resistance and preventing obesity |
| 03/22/2006 | CN1245995C Composition contains spirulina mainly |
| 03/22/2006 | CN1245992C Medicine for treating diabetes nerve end inflammation |
| 03/22/2006 | CN1245988C Use of ATAZANAVIR in HIV therapy |
| 03/22/2006 | CN1245984C Preparation for prevention and/or treatment of vascular disorders |
| 03/22/2006 | CN1245971C Tea poly phenol soft capsule and its preparation process |
| 03/22/2006 | CN1245959C Healthy products for regulating blood fat and removing heat from throat |
| 03/21/2006 | US7015235 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 03/21/2006 | US7015231 such as (3Z)-3-[(1-methyl-1H-indol-3-yl)methylene]-1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one; tyrosine kinase inhibitors; for treatment of tumor growth, restenosis, atherosclerosis, pain and thrombosis |
| 03/21/2006 | US7015229 An antagonist of a corticotropin releasing factor (CRF) receptor, treating central nervous system disorders or anxiety disorders, depression and stress |
| 03/21/2006 | US7015220 enzyme inhibitors used as modulators of tyrosine kinase signal transduction and/or as antiproliferative agents; prophylaxis of vision defects, cancer, atherosclerosis, restenosis, metabolic disorders or autoimmune diseases |
| 03/21/2006 | US7015217 Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 03/21/2006 | US7015216 Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
| 03/21/2006 | US7015213 Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors |
| 03/21/2006 | US7015210 Methods of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
| 03/21/2006 | US7015208 carbocyclic alcohols such as 5-Chloro-2-methylsulfonylindan-1-ol and isomers, used as anorexigenic agents; side effect reduction; nontoxic |
| 03/21/2006 | US7015201 Pyrazole derivatives and diabetic medicine containing them |
| 03/21/2006 | US7015200 Carbohydrates conjugated to optionally protected 4-hydroxybutyric acid; enhance the uptake of the drug and allows effective drug delivery to treat GHB-treatable disorders such as sleep disorders or drug withdrawal |
| 03/21/2006 | US7015015 Nucleotide sequences coding polypeptide for use in treatment of diabetes, epilepsy, depression, ischemia and muscle disorders |
| 03/21/2006 | US7014862 Chewable compositions containing a gel-forming extract of psyllium |
| 03/21/2006 | US7014852 Alkaline phosphatase to induce weight loss or to reduce weight gain |
| 03/21/2006 | US7014846 polyallylamine hydrochloride crosslinked with epichlorohydrin; phosphate removal from gastrointestinal tract; hyperphosphatemia; side effect reduction |
| 03/21/2006 | US7014838 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 03/21/2006 | CA2521933C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 03/21/2006 | CA2399358C Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 03/21/2006 | CA2315220C Integrin receptor antagonists |
| 03/21/2006 | CA2072416C Cyclopropenone derivatives |
| 03/16/2006 | WO2006029371A2 Neuromedin u 2 receptor agonists and uses thereof |
| 03/16/2006 | WO2006029349A1 Combination of organic compounds |
| 03/16/2006 | WO2006028970A1 Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| 03/16/2006 | WO2006028875A1 Phenanthridine carbonyl phenols as cytokine modulators |
| 03/16/2006 | WO2006028239A1 Carbamoyl-substituted spiro derivative |
| 03/16/2006 | WO2006028122A1 Agent for preventing and ameliorating obesity |
| 03/16/2006 | WO2006028120A1 Preventive/remedy for obesity |
| 03/16/2006 | WO2006027223A1 Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
| 03/16/2006 | WO2006027204A1 8-(3-amino-piperidin-1-yl)-7-(but-2-inyl)-xanthines, production thereof and use thereof as medicaments |
| 03/16/2006 | WO2006027052A2 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 03/16/2006 | WO2006017054A3 Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| 03/16/2006 | WO2006016363A3 Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions |
| 03/16/2006 | WO2006004574A3 Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
| 03/16/2006 | WO2005121121A3 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 03/16/2006 | WO2005110457A3 Treatment of eating disorders and induction of lipolysis |
| 03/16/2006 | WO2004110419A8 Agonist agents and medicinal compositions |
| 03/16/2006 | US20060058552 Solid preferably with an aspect ratio of 1 to 4 and a solubility in water at room temperature of at least 425 mg/ml. |
| 03/16/2006 | US20060058533 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 03/16/2006 | US20060058507 Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders |
| 03/16/2006 | US20060058395 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| 03/16/2006 | US20060058385 Combination of antidiabetic drugs |
| 03/16/2006 | US20060058372 N-Benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them |
| 03/16/2006 | US20060058371 Inhibiting pathological activation of the transcription factor NF- kappa B (nuclear factor- kappa B); amino-benzothiophene compounds, therapy of inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease |
| 03/16/2006 | US20060058366 Jnk inhibitor |
| 03/16/2006 | US20060058353 Benzofuran derivatives, process for their preparation and intermediates thereof |
| 03/16/2006 | US20060058350 Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient |
| 03/16/2006 | US20060058349 Piperidinetriol derivatives as inhibitors of glycosyceramid synthase |
| 03/16/2006 | US20060058315 2-Oxo-ethanesulfonamide derivates |